Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of OV101 in Angelman Syndrome
NCT03882918Phase 3Terminated
- Sponsor
- Healx
- Start
- Jan 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of gaboxadol in Angelman syndrome (AS), sponsored by Healx. Started Jan 2019; status: terminated.
02
Drugs
gaboxadol
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on NCT03882918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03882918.